Third-quarter earnings reports from Nucor, SAP, General Motors, Lockheed Martin, Verizon, AT&T, Coca-Cola, Newmont, UPS, and ...

GITEX Global 2024 is showcasing the latest advancements in cybersecurity and artificial intelligence Today the event started with Cybersecurity Day ...

Sixt SE with its headquarters in Pullach near Munich, is a leading international provider of high-quality mobility services. With its products SIXT rent, SIXT share, SIXT ride and SIXT+ on the ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

For the past year, French pharmaceutical giant Sanofi has been searching for a buyer to take control of its consumer health business. That search may now be over. On Friday, Sanofi said it’s in ...

Oct 4 (Reuters) - GSK (GSK.L), opens new tab, Sanofi (SASY.PA), opens new tab and CSL Ltd (CSL.AX), opens new tab have secured $72 million from the U.S. government to ramp up production of bird ...

Sanofi Healthcare Bidders Revising Offers Over Talc Concerns CD&R, PAI look to exclude aspects of Gold Bond unit in bids Consumer business could be valued at €15 billion in a sale ...

GSK Plc, Sanofi, and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human ...

Sanofi is of­fload­ing its rare au­toim­mune dis­ease med­i­cine En­jay­mo to an Ital­ian phar­ma­ceu­ti­cal com­pa­ny for $825 mil­lion up­front.

(Bloomberg) -- Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder ...

Now it’s trading hands again, through a deal announced Friday. Sanofi is selling global rights to Enjaymo to the Italy-based drugmaker Recordati, in exchange for an upfront payment of $825 million.